BEAM241018C30000
- 0.27
- 0.000.00%
Beam Therapeutics Newsroom
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating
Hold Rating on Beam Therapeutics Amid Competitive Pressure and Absence of Clinical Data
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69
Beam Therapeutics Is Maintained at Buy by Stifel
Express News | Beam Therapeutics Inc : Stifel Raises Target Price to $69 From $66
Here's What the Harris-Trump Debate Means for US Stocks
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Optimistic Outlook on Beam Therapeutics: Advancements and Potential in Precision Genetic Medicines
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine With CRISPR Technology
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Express News | RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Beam Therapeutics Analyst Ratings
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)